Alteon to Present at the Punk, Ziegel & Company New Developments in the Treatment of Diabetes Symposium
September 21 2004 - 2:39PM
PR Newswire (US)
Alteon to Present at the Punk, Ziegel & Company New
Developments in the Treatment of Diabetes Symposium Wednesday,
September 22, 2004 PARSIPPANY, N.J., Sept. 21
/PRNewswire-FirstCall/ -- Alteon Inc. (AMEX:ALT) announced today
that Kenneth I. Moch, President and Chief Executive Officer, will
participate in the Punk, Ziegel & Company New Developments in
the Treatment of Diabetes Symposium being held tomorrow, September
22, 2004 at the Four Seasons Hotel, New York. Mr. Moch is scheduled
to present at 10:45 a.m. ET. The live presentation will be webcast
and will be accessible through Alteon's corporate website,
http://www.alteon.com/, or at
http://69.27.168.167/stratosphere/links.htm , where it will be
archived for 30 days. About Alteon Alteon is developing several new
classes of drugs that reverse or slow down diseases of aging and
complications of diabetes. These compounds have an impact on a
fundamental pathological process caused by protein-glucose
complexes called Advanced Glycation End-products (A.G.E.s). The
formation and crosslinking of A.G.E.s lead to a loss of flexibility
and function in body tissues, organs and vessels and have been
shown to be a causative factor in many age-related diseases and
diabetic complications. Alteon has created a library of novel
classes of compounds targeting the A.G.E. Pathway. Alteon's lead
compound alagebrium chloride (formerly ALT-711), the only A.G.E.
Crosslink Breaker in advanced human testing, has demonstrated
safety and efficacy in several Phase 2 trials and is actively being
developed for systolic hypertension and heart failure. Ongoing
clinical trials include SPECTRA (Systolic Pressure Efficacy and
Safety Trial of Alagebrium) and PEDESTAL (Patients with Impaired
Ejection Fraction and Diastolic Dysfunction: Efficacy and Safety
Trial of ALagebrium), as well as a third trial exploring mechanism
of action in endothelial dysfunction. For more information on
Alteon, visit the company's website at http://www.alteon.com/. Any
statements contained in this press release that relate to future
plans, events or performance are forward-looking statements that
involve risks and uncertainties including, but not limited to,
those relating to technology and product development (including the
possibility that early clinical trial results may not be predictive
of results that will be obtained in large-scale testing or that any
clinical trials will not demonstrate sufficient safety and efficacy
to obtain requisite approvals or will not result in marketable
products), regulatory approval processes, intellectual property
rights and litigation, competitive products, ability to obtain
financing, and other risks identified in Alteon's filings with the
Securities and Exchange Commission. The information contained in
this press release is accurate as of the date indicated. Actual
results, events or performance may differ materially. Alteon
undertakes no obligation to publicly release the result of any
revision to these forward-looking statements that may be made to
reflect events or circumstances after the date hereof or to reflect
the occurrence of unanticipated events. DATASOURCE: Alteon Inc.
CONTACT: Susan M. Pietropaolo, Director, Corporate Communications
& Investor Relations of Alteon Inc., +1-201-934-5000, or Fax,
+1-201-934-8880 Web site: http://www.alteon.com/
http://69.27.168.167/stratosphere/links.htm
Copyright
Ishares Diversified Alternatives Trust (AMEX:ALT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ishares Diversified Alternatives Trust (AMEX:ALT)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Ishares Diversified Alternatives Trust (American Stock Exchange): 0 recent articles
More Alteon , News Articles